APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tysabri (natalizumab) Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Tysabri (natalizumab) Drug Market Outlook and Growth Opportunities 2026

22 December 2025196 pages

Choose your research edition.

Industry ResearchTysabri (natalizumab) Drug Industry Research Report 2026108 pages · $2,950 USDIndustry Growth & TrendsGlobal Tysabri (natalizumab) Drug Industry Growth and Trends Forecast to 203274 pages · $3,450 USDMarket StructureGlobal Tysabri (natalizumab) Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032173 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tysabri (natalizumab) Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Tysabri (natalizumab) Drug Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Tysabri (natalizumab) Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Tysabri (natalizumab) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Tysabri (natalizumab) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tysabri (natalizumab) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Tysabri (natalizumab) Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Tysabri (natalizumab) Drug market include Biogen and Novartis among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Tysabri (natalizumab) Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Tysabri (natalizumab) Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Tysabri (natalizumab) Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Tysabri (natalizumab) Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Tysabri (natalizumab) Drug Segment by Company

Biogen

Novartis

Tysabri (natalizumab) Drug Segment by Type

Crohn's Disease

Multiple Sclerosis

Tysabri (natalizumab) Drug Segment by Application

Hospital

Drugs Stores

Tysabri (natalizumab) Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Tysabri (natalizumab) Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Tysabri (natalizumab) Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Tysabri (natalizumab) Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Tysabri (natalizumab) Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tysabri (natalizumab) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tysabri (natalizumab) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tysabri (natalizumab) Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Tysabri (natalizumab) Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Tysabri (natalizumab) Drug industry.

Chapter 3: Detailed analysis of Tysabri (natalizumab) Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Tysabri (natalizumab) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Tysabri (natalizumab) Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Tysabri (natalizumab) Drug Industry Trends Table 2. Tysabri (natalizumab) Drug Industry Drivers Table 3. Tysabri (natalizumab) Drug Industry Opportunities and Challenges Table 4. Tysabri (natalizumab) Drug Industry Restraints Table 5. Global Tysabri (natalizumab) Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Tysabri (natalizumab) Drug Revenue Share by Company (2021-2026) Table 7. Global Tysabri (natalizumab) Drug Sales Volume by Company (k units) & (2021-2026) Table 8. Global Tysabri (natalizumab) Drug Sales Volume Share by Company (2021-2026) Table 9. Global Tysabri (natalizumab) Drug Average Price (US$/unit) of Company (2021-2026) Table 10. Global Tysabri (natalizumab) Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Tysabri (natalizumab) Drug Key Company Manufacturing Base & Headquarters Table 12. Global Tysabri (natalizumab) Drug Company, Product Type & Application Table 13. Global Tysabri (natalizumab) Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Tysabri (natalizumab) Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Crohn's Disease Table 18. Significant Companies of Multiple Sclerosis Table 19. Global Tysabri (natalizumab) Drug Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Tysabri (natalizumab) Drug Sales Volume by Type (2021-2026) & (k units) Table 21. Global Tysabri (natalizumab) Drug Sales Volume by Type (2027-2032) & (k units) Table 22. Global Tysabri (natalizumab) Drug Sales Volume Share by Type (2021-2026) Table 23. Global Tysabri (natalizumab) Drug Sales Volume Share by Type (2027-2032) Table 24. Global Tysabri (natalizumab) Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Tysabri (natalizumab) Drug Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Tysabri (natalizumab) Drug Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Tysabri (natalizumab) Drug Sales Value Share by Type (2021-2026) Table 28. Global Tysabri (natalizumab) Drug Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Drugs Stores Table 31. Global Tysabri (natalizumab) Drug Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Tysabri (natalizumab) Drug Sales Volume by Application (2021-2026) & (k units) Table 33. Global Tysabri (natalizumab) Drug Sales Volume by Application (2027-2032) & (k units) Table 34. Global Tysabri (natalizumab) Drug Sales Volume Share by Application (2021-2026) Table 35. Global Tysabri (natalizumab) Drug Sales Volume Share by Application (2027-2032) Table 36. Global Tysabri (natalizumab) Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Tysabri (natalizumab) Drug Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Tysabri (natalizumab) Drug Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Tysabri (natalizumab) Drug Sales Value Share by Application (2021-2026) Table 40. Global Tysabri (natalizumab) Drug Sales Value Share by Application (2027-2032) Table 41. Global Tysabri (natalizumab) Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Tysabri (natalizumab) Drug Sales by Region (2021-2026) & (k units) Table 43. Global Tysabri (natalizumab) Drug Sales Market Share by Region (2021-2026) Table 44. Global Tysabri (natalizumab) Drug Sales by Region (2027-2032) & (k units) Table 45. Global Tysabri (natalizumab) Drug Sales Market Share by Region (2027-2032) Table 46. Global Tysabri (natalizumab) Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Tysabri (natalizumab) Drug Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Tysabri (natalizumab) Drug Sales Value Share by Region (2021-2026) Table 49. Global Tysabri (natalizumab) Drug Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Tysabri (natalizumab) Drug Sales Value Share by Region (2027-2032) Table 51. Global Tysabri (natalizumab) Drug Market Average Price (US$/unit) by Region (2021-2026) Table 52. Global Tysabri (natalizumab) Drug Market Average Price (US$/unit) by Region (2027-2032) Table 53. Global Tysabri (natalizumab) Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Global Tysabri (natalizumab) Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Tysabri (natalizumab) Drug Sales by Country (2021-2026) & (k units) Table 56. Global Tysabri (natalizumab) Drug Sales Market Share by Country (2021-2026) Table 57. Global Tysabri (natalizumab) Drug Sales by Country (2027-2032) & (k units) Table 58. Global Tysabri (natalizumab) Drug Sales Market Share by Country (2027-2032) Table 59. Global Tysabri (natalizumab) Drug Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Tysabri (natalizumab) Drug Sales Value Market Share by Country (2021-2026) Table 61. Global Tysabri (natalizumab) Drug Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Tysabri (natalizumab) Drug Sales Value Market Share by Country (2027-2032) Table 63. Biogen Company Information Table 64. Biogen Business Overview Table 65. Biogen Tysabri (natalizumab) Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Biogen Tysabri (natalizumab) Drug Product Portfolio Table 67. Biogen Recent Development Table 68. Novartis Company Information Table 69. Novartis Business Overview Table 70. Novartis Tysabri (natalizumab) Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Novartis Tysabri (natalizumab) Drug Product Portfolio Table 72. Novartis Recent Development Table 73. Key Raw Materials Table 74. Raw Materials Key Suppliers Table 75. Tysabri (natalizumab) Drug Distributors List Table 76. Tysabri (natalizumab) Drug Customers List Table 77. Research Programs/Design for This Report Table 78. Authors List of This Report Table 79. Secondary Sources Table 80. Primary Sources List of Figures Figure 1. Tysabri (natalizumab) Drug Product Image Figure 2. Global Tysabri (natalizumab) Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tysabri (natalizumab) Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Tysabri (natalizumab) Drug Sales (2021-2032) & (k units) Figure 5. Global Tysabri (natalizumab) Drug Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Tysabri (natalizumab) Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Crohn's Disease Image Figure 10. Multiple Sclerosis Image Figure 11. Global Tysabri (natalizumab) Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Tysabri (natalizumab) Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Tysabri (natalizumab) Drug Sales Volume Share by Type (2021-2032) Figure 14. Global Tysabri (natalizumab) Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Tysabri (natalizumab) Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Tysabri (natalizumab) Drug Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Drugs Stores Image Figure 19. Global Tysabri (natalizumab) Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Tysabri (natalizumab) Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Tysabri (natalizumab) Drug Sales Volume Share by Application (2021-2032) Figure 22. Global Tysabri (natalizumab) Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Tysabri (natalizumab) Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Tysabri (natalizumab) Drug Sales Value Share by Application (2021-2032) Figure 25. Global Tysabri (natalizumab) Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 26. Global Tysabri (natalizumab) Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Tysabri (natalizumab) Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Tysabri (natalizumab) Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Tysabri (natalizumab) Drug Sales Value (2021-2032) & (US$ Million) Figure 30. North America Tysabri (natalizumab) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Tysabri (natalizumab) Drug Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Tysabri (natalizumab) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Tysabri (natalizumab) Drug Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Tysabri (natalizumab) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Tysabri (natalizumab) Drug Sales Value (2021-2032) & (US$ Million) Figure 36. South America Tysabri (natalizumab) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Tysabri (natalizumab) Drug Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Tysabri (natalizumab) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Tysabri (natalizumab) Drug Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Tysabri (natalizumab) Drug Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Crohn's Disease
  • Multiple Sclerosis
Applications
  • Hospital
  • Drugs Stores
Companies covered
  • Biogen
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Tysabri (natalizumab) Drug Sales Value (2021-2032)
  4. 1.2.2 Global Tysabri (natalizumab) Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Tysabri (natalizumab) Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Tysabri (natalizumab) Drug Market Dynamics
  1. 2.1 Tysabri (natalizumab) Drug Industry Trends
  2. 2.2 Tysabri (natalizumab) Drug Industry Drivers
  3. 2.3 Tysabri (natalizumab) Drug Industry Opportunities and Challenges
  4. 2.4 Tysabri (natalizumab) Drug Industry Restraints
3 Tysabri (natalizumab) Drug Market by Company
  1. 3.1 Global Tysabri (natalizumab) Drug Company Revenue Ranking in 2025
  2. 3.2 Global Tysabri (natalizumab) Drug Revenue by Company (2021-2026)
  3. 3.3 Global Tysabri (natalizumab) Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Tysabri (natalizumab) Drug Average Price by Company (2021-2026)
  5. 3.5 Global Tysabri (natalizumab) Drug Company Ranking (2024-2026)
  6. 3.6 Global Tysabri (natalizumab) Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Tysabri (natalizumab) Drug Company Product Type and Application
  8. 3.8 Global Tysabri (natalizumab) Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Tysabri (natalizumab) Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Tysabri (natalizumab) Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Tysabri (natalizumab) Drug Market by Type
  1. 4.1 Tysabri (natalizumab) Drug Type Introduction
  2. 4.1.1 Crohn's Disease
  3. 4.1.2 Multiple Sclerosis
  4. 4.2 Global Tysabri (natalizumab) Drug Sales Volume by Type
  5. 4.2.1 Global Tysabri (natalizumab) Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Tysabri (natalizumab) Drug Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Tysabri (natalizumab) Drug Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Tysabri (natalizumab) Drug Sales Value by Type
  9. 4.3.1 Global Tysabri (natalizumab) Drug Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Tysabri (natalizumab) Drug Sales Value by Type (2021-2032)
  11. 4.3.3 Global Tysabri (natalizumab) Drug Sales Value Share by Type (2021-2032)
5 Tysabri (natalizumab) Drug Market by Application
  1. 5.1 Tysabri (natalizumab) Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Drugs Stores
  4. 5.2 Global Tysabri (natalizumab) Drug Sales Volume by Application
  5. 5.2.1 Global Tysabri (natalizumab) Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Tysabri (natalizumab) Drug Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Tysabri (natalizumab) Drug Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Tysabri (natalizumab) Drug Sales Value by Application
  9. 5.3.1 Global Tysabri (natalizumab) Drug Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Tysabri (natalizumab) Drug Sales Value by Application (2021-2032)
  11. 5.3.3 Global Tysabri (natalizumab) Drug Sales Value Share by Application (2021-2032)
6 Tysabri (natalizumab) Drug Regional Sales and Value Analysis
  1. 6.1 Global Tysabri (natalizumab) Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Tysabri (natalizumab) Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Tysabri (natalizumab) Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Tysabri (natalizumab) Drug Sales by Region (2027-2032)
  5. 6.3 Global Tysabri (natalizumab) Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Tysabri (natalizumab) Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Tysabri (natalizumab) Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Tysabri (natalizumab) Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Tysabri (natalizumab) Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Tysabri (natalizumab) Drug Sales Value (2021-2032)
  12. 6.6.2 North America Tysabri (natalizumab) Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Tysabri (natalizumab) Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Tysabri (natalizumab) Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Tysabri (natalizumab) Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Tysabri (natalizumab) Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Tysabri (natalizumab) Drug Sales Value (2021-2032)
  21. 6.9.2 South America Tysabri (natalizumab) Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Tysabri (natalizumab) Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Tysabri (natalizumab) Drug Sales Value Share by Country, 2025 VS 2032
7 Tysabri (natalizumab) Drug Country-level Sales and Value Analysis
  1. 7.1 Global Tysabri (natalizumab) Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Tysabri (natalizumab) Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Tysabri (natalizumab) Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Tysabri (natalizumab) Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Tysabri (natalizumab) Drug Sales by Country (2027-2032)
  6. 7.4 Global Tysabri (natalizumab) Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Tysabri (natalizumab) Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Tysabri (natalizumab) Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Tysabri (natalizumab) Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Tysabri (natalizumab) Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Tysabri (natalizumab) Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Biogen
  2. 8.1.1 Biogen Company Information
  3. 8.1.2 Biogen Business Overview
  4. 8.1.3 Biogen Tysabri (natalizumab) Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Biogen Tysabri (natalizumab) Drug Product Portfolio
  6. 8.1.5 Biogen Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Tysabri (natalizumab) Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Tysabri (natalizumab) Drug Product Portfolio
  12. 8.2.5 Novartis Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Tysabri (natalizumab) Drug Value Chain Analysis
  2. 9.1.1 Tysabri (natalizumab) Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Tysabri (natalizumab) Drug Sales Mode & Process
  6. 9.2 Tysabri (natalizumab) Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Tysabri (natalizumab) Drug Distributors
  9. 9.2.3 Tysabri (natalizumab) Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst